MGTX News and Press, MeiraGTx Holdings plc From 11/19/20

Shares of MeiraGTx Holdings (NASDAQ:MGTX) -- a clinical-stage biotech company -- are down by 11.51% as of 11:55 a.m. EST on Thursday, following the company's announcement of the pricing of a public offering of common stock. Investors aren't thrilled with the prospect of MeiraGTx dil...

Gainers: Naked Brand (NAKD) +116%.Phoenix New Media (FENG) +48%.Titan Pharmaceuticals (TTNP) +36%.HighPoint Resources (HPR) +32%.Arcimoto (FUV) +32%.Ayro (AYRO) +29%.CIIG Merger (CIIC) +27%.Aptevo Therapeutics (APVO) +27%.Sonos (SONO) +27%.Blink Charging (BLNK) +23%.Losers: Ebang In...

Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%,&#x...

X Financial (XYF) -33%.MeiraGTx Holdings (MGTX) -10% on public offering pricing at $12.85/share.Tantech Holdings (TANH) -9%.BeyondSpring (BYSI) -9% on public offering pricing at $10.0/share.Chindata Group Holdings (CD) -7% on Q3 earnings release.Phoenix Tree Hold...

MeiraGTx (MGTX) slips 10% in premarket, after pricing its previously announced public offering of 5M shares at $12.85/share, for gross proceeds of ~$64.3M.Offer price represents discount of ~11% over last close price of $14.36.The offering is expected to close by November 23. For ...

MeiraGTx (MGTX) -2.2% AH, commenced an underwritten public offering of 5M shares; underwriters granted 30-day option to purchase up to an additional 750K shares.Offer terms and size have not yet been disclosed.Proceeds to be used for general corporate purposes, including working cap...

MeiraGTx ([[MGTX]] +2.5%) has announced 12-month data from the ongoing Phase 1/2 trial of AAV-RPGR, an investigational gene therapy for the treatment of X-linked retinitis pigmentosa ((XLRP)). Data were presented at the American Academy of Ophthalmology.The primary endpoint of the trial is sa...

LONDON and NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced 12-month data from the ongoing Phase 1/2 clinical trial ( NCT03252847 ) of AAV-RPGR, an investigational gene th...

LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barcl...

MeiraGTx (MGTX): Q3 GAAP EPS of -$0.17 beats by $0.52.Revenue of $5.1M (+42.5% Y/Y) beats by $4.19M.Press Release For further details see: MeiraGTx EPS beats by $0.52, beats on revenue